It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Zinc metabolism at the cellular level is critical for many biological processes in the body. A key observation is the disruption of cellular homeostasis, often coinciding with disease progression. As an essential factor in maintaining cellular equilibrium, cellular zinc has been increasingly spotlighted in the context of disease development. Extensive research suggests zinc’s involvement in promoting malignancy and invasion in cancer cells, despite its low tissue concentration. This has led to a growing body of literature investigating zinc’s cellular metabolism, particularly the functions of zinc transporters and storage mechanisms during cancer progression. Zinc transportation is under the control of two major transporter families: SLC30 (ZnT) for the excretion of zinc and SLC39 (ZIP) for the zinc intake. Additionally, the storage of this essential element is predominantly mediated by metallothioneins (MTs). This review consolidates knowledge on the critical functions of cellular zinc signaling and underscores potential molecular pathways linking zinc metabolism to disease progression, with a special focus on cancer. We also compile a summary of clinical trials involving zinc ions. Given the main localization of zinc transporters at the cell membrane, the potential for targeted therapies, including small molecules and monoclonal antibodies, offers promising avenues for future exploration.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Hong Kong, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482); The Chinese University of Hong Kong, State Key Laboratory of Digestive Disease, Institute of Digestive Disease, Hong Kong, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482); The Chinese University of Hong Kong, CUHK-Shenzhen Research Institute, Shenzhen, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482)
2 Southern Medical University, Guangdong Province Key Laboratory of Molecular Tumor Pathology, Department of Pathology, Nanfang Hospital and Basic Medical College, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471)
3 Taihe Hospital, Hubei University of Medicine, Institute of Biomedical Research, Shiyan, China (GRID:grid.443573.2) (ISNI:0000 0004 1799 2448)
4 The Chinese University of Hong Kong, Department of Pediatrics, Hong Kong, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482)
5 Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Hong Kong, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482)
6 The Chinese University of Hong Kong, State Key Laboratory of Digestive Disease, Institute of Digestive Disease, Hong Kong, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482); The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482)
7 Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Hong Kong, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482); The Chinese University of Hong Kong, State Key Laboratory of Digestive Disease, Institute of Digestive Disease, Hong Kong, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482)